FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Smith Karen L. 2. Date of Event Requiring Statement (MM/DD/YYYY)
5/21/2020 

3. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]
(Last)       (First)       (Middle)
400 PROFESSIONAL DRIVE, SUITE 400
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Chief Medical Officer /
(Street)
GAITHERSBURG,, MD 20879      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  6310 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Options (Right to Buy)   (2) 5/7/2027  Common Stock  12619.0  $79.25  D   

Explanation of Responses:
(1)  Consists of 3,155 unvested PSUs and 3,155 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU and each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of GAAP revenue on a cumulative basis over the three-year period beginning on January 1, 2020 and ending on December 31, 2022, as certified by the Compensation Committee following the performance period. The RSUs vest annually in three equal installments beginning on the day prior to the anniversary date of the grant, or 05/07/2020.
(2)  Vests in three equal installments beginning on the day prior to the anniversary date of the grant, or 05/07/2020.

Remarks:
Exhibit list: Ex 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Smith Karen L.
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG,, MD 20879


EVP, Chief Medical Officer

Signatures
S. Scott Lieberman, Attorney-in-fact 5/28/2020
**Signature of Reporting Person Date
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Emergent Biosolutions Charts.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Emergent Biosolutions Charts.